Skip to main content
. 2022 Nov 7;20(11):e3001351. doi: 10.1371/journal.pbio.3001351

Fig 5. LPS, type I and type II interferons increase Pyrin expression and enable Pyrin activation in human macrophages.

Fig 5

(A) Pyrin and IL-1β expression in hMDM treated with either IFN-γ (200 U/ml), LPS (10 ng/ml), TNFα (50 ng/ml), IL-10 (100 ng/ml), IFN-β (5,000 U/ml), IL-4 (1,000 U/ml), or Pam3CSK4 (20 ng/ml) for either 5 or 18 h. Representative of 3 independent experiments. (B) Pyrin (MEFV) or IL-1β (IL1β) transcript from hMDM-treated LPS (10 ng/ml) or Pam3CSK4 (20 ng/ml) for 12 h. Mean and SEM of the fold change of 3 experimental replicates shown. The underlying data can be found in the summary data file in the tab Fig 5B.